/
Amgen Inc. (including its subsidiaries, referred to as Amgen, the Company, we, our or us ) discovers, develops, manufactures and delivers innovative medicines to fight some of the world s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people s lives, while also reducing the social and economic burden o…
$336.79
+$0.31 (+0.09%)
Price from 7 days ago
24.71% operating margin is above average. ROIC at 11.95%.
Revenue grew 10.0%, steady but not accelerating. Free cash flow declined 22% despite revenue growth, conversion is weakening.
Free cash flow declined 22% versus the prior year, cash generation momentum has weakened. Net debt of $46.31B represents 5.7x FCF, leverage limits flexibility.
23.4x earnings, 21.3x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$37.22B
▲ +10.0% YoY
Net Income (TTM)
$7.80B
▲ +88.5% YoY
Op. Margin
28.39%
▲ +3.0pp YoY
ROIC
14.36%
▲ +2.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$8.60B
▼ -22.1% YoY
Op. Cash Flow (TTM)
$10.76B
▼ -13.3% YoY
Net Debt
$45.28B
Cash & Equiv.
$12.04B
5Y CAGR: +7.6%
5Y CAGR: -3.9%
Continue Research